Stock Price Quote

TITAN BIO-TECH LTD.

NSE : NABSE : 524717ISIN CODE : INE150C01029Industry : ChemicalsHouse : Private
BSE404.90-10.65 (-2.56 %)
PREV CLOSE ( ) 415.55
OPEN PRICE ( ) 422.45
BID PRICE (QTY) 398.05 (77)
OFFER PRICE (QTY) 404.85 (58)
VOLUME 30405
TODAY'S LOW / HIGH ( )394.80 422.45
52 WK LOW / HIGH ( ) 131555.65
NSE
This Company is not listed in NSE
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-02 1992
Management Info
Rohit Jain - Chairman Suresh Chand Singla - Managing Director
Registered Office

Address A - 902 A,R I I C O Industrial Area,Phase 3,
Bhiwadi,
Rajasthan-301019

Phone 011-27355742 / 27674615

Email hrd@titanbiotechltd.com / accounts@titanbiotechltd.com / purchase@titanbiotechltd.com

Website www.titanbiotechltd.com / www.tmmedia.in

Registrars Details
Beetal Financial & Computer Services (P) Ltd
Beetal House , 99 Mandangir,3rd Floor, Behind Local Shopping Centre,Near Dada Harsukhdas Mandir,New Delhi
Listing : BSE

NEWS

07Sep Titan Biotech informs about newspaper
Pursuant to Regulation 30 and other applicable provisions of the Securit..
04Sep Titan Biotech informs about press rele
Titan Biotech has informed that it enclosed Newspaper advertisement rega..
25Jun Titan Biotech informs about loss of sh
Pursuant to Regulation 39(3) of the Listing Regulations, Titan Biotech h..
23Jun Titan Biotech informs about trading wi
Titan Biotech has informed that the trading window for dealing in securi..
01Jun Titan Biotech informs about press rele
Titan Biotech has informed that it enclosed Newspaper publication of the..

Financials

in Millions
QTR Jun 26 ANNUAL 26
Net Profit94.55274.46
Gross Profit 127.33 381.73
Operating Profit 142.99440.12
Net Sales 591.672061.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Solar Industries Ind (BSE)
peergroup  22415.00 (2.33%)
M.Cap ( in Cr)202876.44
Elantas Beck India (BSE)
peergroup  13345.00 (2.48%)
M.Cap ( in Cr)10725.72
Tanfac Industries (BSE)
peergroup  3560.50 (3.63%)
M.Cap ( in Cr)7444.44
Yasho Industries (BSE)
peergroup  4095.00 (2.57%)
M.Cap ( in Cr)4932.68
Gujarat Fluorochem. (BSE)
peergroup  4600.25 (1.59%)
M.Cap ( in Cr)50366.23

Shareholding Pattern

PROMOTERS 55.78%
NON-INSTITUTION 44.21%
FI/BANKS/INSURANCE 0.01%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%
FII 0%

About Titan Bio-Tech Ltd.

Titan Bio-Tech Ltd. was incorporated in the year 1992. Its today's share price is 404.9. Its current market capitalisation stands at Rs 1685.79 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1564.51 Cr and Total Income of Rs.1603.63 Cr. The company's management includes Charanjit Singh, Debendra Kumar Sabat, Brijesh Kumar Singh, Dhairya Madan, Abhishek Agarwal, Rohit Jain, Supriya Singla, Manju Singla, Udit Singla, Shivom Singla, Raja Singla, Suresh Chand Singla, Naresh Singla.

It is listed on the BSE with a BSE Code of 524717 , NSE with an NSE Symbol of and ISIN of INE150C01029. It's Registered office is at A - 902 A,R I I C O Industrial Area,Phase 3Bhiwadi-301019, Rajasthan. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are ANSK & Associates, Deepika Setia & Co, Sunita Agrawal & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.